16 years of Clinical experience, 6 years of basic research and 14 years of drug development.
Key areas of interest include
I qualified as a medical doctor from University of Copenhagen (Denmark) and have license to practice medicine as a specialist in medical and radiation oncology including a certification to treat patients with radioligands. After 4 years in general medicine and oncology, I entered a PhD program which resulted in a PhD from University of Copenhagen, this led to a post-doctoral fellowship at Vanderbilt university medical center, Nashville, Tennessee. I have more than 30 peer-reviewed publications and some submitted for review.
I am a physician-scientist (MD and PhD) by background and have academic expertise in all solid tumors both in terms of medical oncology, radiotherapy as well as radio-ligand treatment.
I have 16 years (since 2005) of expertise as senior medical director, medical director, and medical advisor in several pharmaceutical companies - Novartis Denmark, Genmab Denmark, Topotarget Denmark, Merck KGaA, Germany and Debiopharm Lausanne, Switzerland.
During these years I have been medical lead of several oncology drugs e.g. SOM203, and sandostatin, zalutumumab (a human monoclonal antibody targeting the EGF receptor), Belinostat (HDAC inhibitor - has been approved by FDA) pimasertib (a MEK1/2 inhibitor), Peposertib (a DNA damage and repair inhibitor), Debio 0123 (a Wee1 inhibitor) and 1143 (xevinapant – an IAP inhibitor).
Medical-Scientific expertise in Global Clinical Development Phases I - III, such as:
As a person I am concrete, realistic, and practical, I also thrive on the experimental aspects of drug development with a logical and reasonable approach. I am also questioning data and like to bridge the gap between non-clinical research and clinical study protocols. When confronted with problems I have been told that I can appear quiet, but this is my way of contextualizing, visualizing, and solving problems or issues. I have over the years been involved in numerous early clinical assets and have led clinical development from the non-clinical phase through phase I and II and often we feedback into non-clinical setting (from bench to bed and back). In these situations, I have been commended that with my high level of clinical expertise and non-clinical expertise, it has been of value to the company to design smart studies. Over the years I have also developed a big key opinion leader network in several malignant diseases.